Krzysztof Palczewski

US Patent:

7706863, Apr 27, 2010

Filed:

Aug 26, 2004

Appl. No.:

10/926780

Inventors:

Yoshikazu Imanishi - Seattle WA, US
Krzysztof Palczewski - Bellevue WA, US
Bryan S. Sires - Seattle WA, US
Eric J. Seibel - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61B 6/00

US Classification:

600473, 351200, 600317, 600318

Abstract:

In one aspect the present invention provides methods for assessing a physiological state of a mammalian retina in vivo, the methods of this aspect of the invention each include the steps of: (a) irradiating a portion of a mammalian retina, in vivo, with light having a wavelength in the range of from 600 nm to 1000 nm at an intensity sufficient to stimulate two-photon-induced fluorescence in the retina; and (b) assessing a physiological state of the retina by analyzing the fluorescence.

US Patent:

7951841, May 31, 2011

Filed:

Jun 20, 2005

Appl. No.:

11/629875

Inventors:

Krzysztof Palczewski - Bay Village OH, US
Matthew Batten - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61K 31/215
C07C 67/02

US Classification:

514529, 560249

Abstract:

Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.

US Patent:

8324270, Dec 4, 2012

Filed:

Feb 10, 2009

Appl. No.:

12/368427

Inventors:

Tadao Maeda - Mayfield Heights OH, US
David Saperstein - Seattle WA, US
Krzysztof Palczewski - Bay Village OH, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61K 31/215
A61K 31/21

US Classification:

514529, 514506, 514914

Abstract:

A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C-Cmonocarboxylic acids and C-Cpolycarboxylic acids.

US Patent:

8338394, Dec 25, 2012

Filed:

Oct 9, 2007

Appl. No.:

12/445100

Inventors:

Krzysztof Palczewski - Bay Village OH, US
Radu A. Moise - Cleveland Heights OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 31/59

US Classification:

514168, 514866, 514909

Abstract:

A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.

US Patent:

8346345, Jan 1, 2013

Filed:

Mar 11, 2010

Appl. No.:

12/722314

Inventors:

Yoshikazu Imanishi - Seattle WA, US
Krzysztof Palczewski - Bellevue WA, US
Bryan S. Sires - Seattle WA, US
Eric J. Seibel - Seattle WA, US

Assignee:

University of Washington - Seattle WA

International Classification:

A61B 6/00

US Classification:

600473, 351200, 600317, 600318

Abstract:

In one aspect the present invention provides methods for assessing a physiological state of a mammalian retina in vivo, the methods of this aspect of the invention each include the steps of (a) irradiating a portion of a mammalian retina, in vivo, with light having a wavelength in the range of from 600 nm to 1000 nm at an intensity sufficient to stimulate two-photon-induced fluorescence in the retina; and (b) assessing a physiological state of the retina by analyzing the fluorescence.

US Patent:

20020142385, Oct 3, 2002

Filed:

Aug 3, 2001

Appl. No.:

09/922494

Inventors:

Masashi Miyano - Hyogo, JP
Takashi Kumasaka - Hyogo, JP
Tetsuya Hori - Hyogo, JP
Hiroyuki Motoshima - Hyogo, JP
Tetsuji Okada - Hyogo, JP
Masaki Yamamoto - Hyogo, JP
Krzysztof Palczewski - Seattle WA, US
Craig Behnke - Seattle WA, US
Brian Fox - Seattle WA, US
Isolde Trong - Seattle WA, US
David Teller - Seattle WA, US
Ronald Stenkamp - Seattle WA, US

International Classification:

C07K014/705
C07H021/04
C12P021/02
C12N005/06

US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

The present invention discloses a three-dimensional structure of bovine rhodopsin. There is provided a G protein-coupled receptor selected from the group consisting of the following (a) and (b): (a) a G protein-coupled receptor having three-dimensional structure I defined by the atomic coordinates as shown in Table 1; (b) a G protein-coupled receptor having three-dimensional structure II defined by derived coordinates from the atomic coordinates as shown in Table 1, wherein the mean residual of the discrepancies between the positions of the carbon atoms in the amino acid residues of seven helix sites H-I (36-64), H-II (71-100), H-III (107-139), H-IV (151-173), H-V (200-225), H-VI (247-277) and H-VII (286-306) in the amino acid sequence as shown in SEQ ID NO: 1 of the three-dimensional structure I and the positions of the corresponding carbon atoms in the amino acid residues of the corresponding seven helix sites of the three-dimensional structure II is 1.5 or less when an image of the three-dimensional structure I obtained by computer-processing the atomic coordinates of Table 1 and an image of the three-dimensional structure II obtained by computer-processing the derived coordinates are superposed.

US Patent:

20030097670, May 22, 2003

Filed:

Nov 21, 2001

Appl. No.:

09/990185

Inventors:

Krzysztof Palczewski - Bellevue WA, US
Ning Li - San Diego CA, US
Juan Ballesteros - Encinitas CA, US

International Classification:

A01K067/027
C12P021/02
C12N005/06
C07K014/705

US Classification:

800/018000, 435/354000, 435/320100, 530/350000

Abstract:

The invention provides a gene targeting construct containing a transgene encoding a polypeptide that contains a rod outer segment (ROS) targeting signal. The transgene is flanked by 5′ and 3′ DNA sequences that are homologous to the rhodopsin gene. Homologous recombination between the construct and a rhodopsin gene results in operable association between the transgene and a rod-specific regulatory sequence. The invention also provides cells and animals whose genome contain a functional disruption of one or both endogenous rhodopsin gene alleles, and a transgene encoding a polypeptide that contains a ROS targeting signal operably associated with a rod-specific regulatory sequence. The invention constructs, cell and animals can be used to isolate transgenic polypeptides from the ROS membrane.

US Patent:

20040242704, Dec 2, 2004

Filed:

Mar 15, 2004

Appl. No.:

10/801078

Inventors:

Krzysztof Palczewski - Bellevue WA, US
Shalesh Kaushal - Gainesville FL, US
Vladimir Kuksa - Seattle WA, US
Syed Noorwez - Gainesville FL, US

International Classification:

A61K031/11
C12N009/02

US Classification:

514/703000

Abstract:

Methods and compositions for stabilizing opsin protein in a vertebrate visual system are provided by administration of opsin-binding synthetic retinoids.